Patents Examined by Nora Rooney
  • Patent number: 10073084
    Abstract: This present invention provides a method of predicting immunogenicity and hypersensitivity or allergic reactions to chemical compounds, therapeutics, cosmetics and other chemical compositions. The method uses an in vitro assay employing autologous blood derived cells and an autologous cultured skin biopsy and is of particular utility in the identification and prediction of skin sensitizers that cause allergic contact dermatitis.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 11, 2018
    Assignee: Alcyomics LTD
    Inventor: Anne Dickinson
  • Patent number: 10072053
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: September 11, 2018
    Assignee: Immunomic Therapeutics, Inc.
    Inventors: William Hearl, Teri Heiland
  • Patent number: 10071157
    Abstract: The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: September 11, 2018
    Assignee: MURDOCH CHILDRENS RESEARCH INSTITUTE
    Inventor: Mimi Lai-Kuan Tang
  • Patent number: 10064936
    Abstract: Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Kari C. Nadeau
  • Patent number: 10053497
    Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: August 21, 2018
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
  • Patent number: 10047152
    Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie Orengo, Andrew J. Murphy
  • Patent number: 10047153
    Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: August 14, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie Orengo, Andrew J. Murphy
  • Patent number: 10041958
    Abstract: The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 7, 2018
    Assignee: VETICA LABS, INC.
    Inventors: Juan Estruch, Genevieve Hansen
  • Patent number: 10041943
    Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: August 7, 2018
    Assignee: Diagnostic Hybrids, Inc.
    Inventor: James L Brown
  • Patent number: 10040869
    Abstract: Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 26, 2013
    Date of Patent: August 7, 2018
    Assignee: OMRIX BIOPHARMACEUTICALS LTD.
    Inventors: Israel Nur, Yehuda Shoenfeld, Miri Blank
  • Patent number: 10022440
    Abstract: The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: July 17, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Clive Henry Wasserfall, Mark A. Atkinson, Benjamin George Keselowsky, Young Mee Yoon
  • Patent number: 10022438
    Abstract: An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 17, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yuan Chang, Patrick S. Moore
  • Patent number: 10023900
    Abstract: The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amount
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: July 17, 2018
    Assignee: ALK-ABELLO A/S
    Inventor: Ulla Seppälä
  • Patent number: 10016475
    Abstract: The present invention provides a composition for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders. The composition according to the present invention has excellent inhibitory activities for IL-4 generation, the degranulation of mast cells, COX-2, 15-NOX, and the passing of allergens from through an intestinal epithelial cell layer, or an excellent Treg cell inducing activity.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: July 10, 2018
    Assignee: KOREA FOOD RESEARCH INSTITUTE
    Inventors: Dong-Hwa Shon, Hee-Soon Shin, Min-Jung Bae, Ok-Hee Chai, Chang-Yuil Kang, Dae-Woon Choi, Gye-Young Choi, Jeong-Hae Rho, Jeong-Ryong Do
  • Patent number: 10006903
    Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: June 26, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6
    Inventors: Jocelyne Just, Benedicte Michaud, Jean-Francois Bach, Lucienne Chatenoud
  • Patent number: 9975932
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9970942
    Abstract: Methods and systems for detecting allergens using mass spectrometry are provided herein. In some aspects, a sample can be screened for the presence or quantity of ovalbumin, lysozyme, casein (isoform S1 and S2), lactoglobulin, high and low glutens, wheat, rye, oats, barley, mustard, sesame, and various types of nuts including macadamia, pistachio, brazil, walnuts, peanuts and hazelnuts by detecting one or more peptides specific to the allergen of interest using selected MRM transitions.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: May 15, 2018
    Assignee: DH Technologies Development Pte. Ltd.
    Inventors: Stephen J. Lock, Subhasish Purkayastha, Brian L. Williamson, Keling Dong
  • Patent number: 9963489
    Abstract: An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 8, 2018
    Assignee: BIOMAY AG
    Inventors: Rudolf Valenta, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
  • Patent number: 9962437
    Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 8, 2018
    Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
  • Patent number: 9964540
    Abstract: Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+ T cells in a biological sample of said subject; (b) detecting a frequency of a Th2a subset of the CD4+ T cells in the biological sample; and (c) comparing the frequency of the Th2a subset with the frequency of the CD4+ T cells.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: May 8, 2018
    Assignee: Benaroya Research Institute
    Inventors: William W. Kwok, Erik Wambre